Credits: White House (Daniel Torok) — public domain.
In Washington, on January 6, 2026, Donald Trump said he had secured from Emmanuel Macron a price increase. This increase concerns medications in France, potentially up to 200%, according to his statements. He brandished the threat of 25% tariffs on drugs. Paris denies this and reminds that these prices are governed by health and budgetary procedures. Behind the scenes, a largely narrative tug-of-war aimed at the American public over a volatile issue: the cost of treatments.
A Sequence Of Domestic Politics Exported To The Diplomatic Stage
On January 6, 2026, in Washington, Donald Trump, President of the United States, recycled a familiar narrative. In late December 2025, he mentioned a phone exchange with Emmanuel Macron, President of the French Republic. During that call, he said he had forced Macron to accept a 200% increase in the price of medicines in France.
On January 7, 2026, the Élysée issued a denial: no concession had been granted and, above all, the setting of reimbursable drug prices in France follows a regulatory framework. Beyond the denial, the episode highlights a highly political use of the international stage: a technical subject turned into a display of authority.
What Trump Claims About Drug Prices — And What The Élysée Denies
In his version, Donald Trump describes a conversation in which he demanded that France sharply raise its prices — citing an increase of 200% or more — to “rebalance” a market he deems unfavorable to Americans. He often accompanies this type of narrative with a commercial threat: tariffs of up to 25% on French or European products.
This narrative fits a consistent political line. Trump claims the United States pays for drugs “much more” than Europe. Therefore, they would indirectly subsidize foreign health systems. The logic he proposes is simple, almost mechanical: if others pay more, drugmakers would have less reason to make up their margins in the United States.
On the French side, the Élysée denies any concession on drug prices and points to the institutional framework. Even if a phone exchange took place, the presidency cannot alone decree a price increase. Indeed, a generalized increase in pharmacy prices requires other interventions. The French response was all the more cautious because the diplomatic agenda between Paris and Washington remains full, notably on European security matters.
Drug Price Regulation In France: Who Decides?
France roughly separates two spheres.
On one hand, reimbursable medicines (those covered by Assurance Maladie, fully or partially). Their price is regulated: it results from a process involving medical assessment, economic negotiation, and then administrative decisions.
On the other hand, non-reimbursable medicines. Their price is in principle free, which can lead to variations depending on point of sale and timing.
For reimbursable medicines, the chain is structured:
- The Haute Autorité de santé (HAS) assesses medical benefit and the drug’s place.
- The Comité économique des produits de santé (CEPS) negotiates the price, most often by conventions, with companies. This takes place within a framework of public orientations.
- The competent ministers then issue decisions, according to prescribed procedures.
In other words, even if the executive sets orientations, the final price is the product of a broader mechanism. This mechanism is based on assessments and negotiations. It is this framework that the Élysée highlights to put the scope of the narrative into perspective. Indeed, the story is presented as a personal “agreement.”
For patients, this architecture has a concrete effect: the pharmacy shelf price is not just a “market” price. In reality, it’s a balance between access to treatments, sustainability of public spending, and remuneration for innovation.
Drug Prices In The United States: Why They Remain Higher Than In Europe
In the United States, the cost of prescription drugs has fueled a cross-cutting debate for years. It weighs on households, insurers, and public finances. In a drug prices US–Europe comparison, the American bill often appears higher, in a system where negotiations pass through many actors (insurers, pharmacy networks, intermediaries), without a single “administered” price.
Since his return to power, Donald Trump has promoted a guiding idea: obtain, by coercion or new rules, price levels more favorable to American patients. In this logic, Europe is presented as a counter-model and sometimes as a “beneficiary” of lower prices. Consequently, the subject is politically effective, even if the real mechanisms are more complex.
Tariffs (25%) On Drugs: A Real Lever, Uncertain Outcome
The threat of 25% tariffs fits a practice already seen under Trump’s terms: using trade as a political bargaining tool. Legally and economically, the United States can indeed impose tariffs on imports, including European ones.
But the lever’s effectiveness is less obvious than the slogan.
First, a tariff increase targets imported products; it does not automatically change administered prices in a foreign health system. In France, even if the executive decided to revise its strategy, that would require technical and budgetary discussions. Moreover, those discussions would be accompanied by regulated decisions.
Finally, the pharmaceutical sector is particular. States want to secure access to essential treatments and limit shortages. A commercial confrontation, amid fragile global production chains, can become politically risky. That includes risks for the party that triggers it.
A Often Personalized Trump–Macron Relationship
The episode fits into an already highly personalized relationship. Between Trump and Macron, diplomacy has often been reduced to scenes and symbols: scrutinized gestures, replayed lines, narratives of victories or frustrations.
The scenario of a “won” call follows that grammar: it shows a leader claiming to be able to achieve, alone, a dramatic result. Paris, for its part, refers to institutions and avoids escalation, at the risk of ceding the media space to the loudest narrator.
What Can Be Verified, What Cannot
Three elements can be established without difficulty.
- Donald Trump did publicly make statements describing an exchange with Emmanuel Macron. He mentioned a very large increase in drug prices.
- The Élysée did issue a denial, reminding that the French president does not set drug prices alone.
- The question of drug prices is a politically inflammable issue in the United States. Indeed, comparison with Europe regularly fuels promises and controversies.
However, the precise reality of the exchange remains not publicly established. The exact content of the call and its tone remain unknown. Moreover, the existence of an “agreement” is not confirmed. By nature, a bilateral conversation cannot be proven by a stage imitation. And no change in French doctrine was announced thereafter.
Concrete Stakes For France And The Pharmaceutical Industry
In the short term, the sequence does not mechanically announce a price increase in France. But it recalls that drugs can become, on the American side, a commercial pressure tool.
For the pharmaceutical industry, this means more uncertainty. Indeed, production, supply, and launch decisions are made over several years. Additionally, tariff threats, even without immediate effects, weigh on calculations.
For the French state, the challenge is to maintain a steady line: guarantee access to treatments and control spending. Furthermore, it is about supporting health sovereignty without giving the impression of negotiating under ultimatum. For patients, the focus remains clarity: a spectacular percentage alone does not say what concerns list price, reimbursement, or out-of-pocket cost.
Practical Points Of Reference
- Prices of reimbursable medicines are regulated and can be consulted via the French public database.
- The reimbursement rate depends on medical situation, product type, and Assurance Maladie rules.
- Significant price changes practically require administrative decisions, conventions, and budgetary trade-offs; they are not instantaneous.
Largely Rhetorical Tug-Of-War, With No Immediate Effect
The Trump–Macron sequence on drug prices illustrates a classic tension: a technical, complex, and regulated subject becomes a political communication tool, presented as a personal victory. The Élysée’s denial recalls the reality of the French system: drug prices, especially reimbursable ones, are not decided in a one-on-one meeting.
One lasting fact persists: in the United States, the battle over the cost of drugs continues to drive aggressive strategies. These include commercial approaches, which can ultimately affect transatlantic balances.
Video unavailable